Long Term Outcome of Intravitreal Therapy with Pegaptanib Sodium in an Infant with Active Retinitis due to Postnatally Acquired Cytomegalovirus Infection

Cinzia Auriti¹, Fiammetta Piersigilli^1, and Gino Catena²

¹Department of Medical and Surgical Neonatology, Bambino Gesu’ Chldren’s Hospital (IRCCS) Rome, Italy

²Department of Ophtalmology, Bambino Gesu’ Chldren’s Hospital (IRCCS) Rome, Italy

Cite this paper:
Cinzia Auriti, Fiammetta Piersigilli and Gino Catena. Long Term Outcome of Intravitreal Therapy with Pegaptanib Sodium in an Infant with Active Retinitis due to Postnatally Acquired Cytomegalovirus Infection. American Journal of Medical Case Reports. 2015; 3(7):209-211. doi: 10.12691/ajmcr-3-7-7

Abstract

We describe the case of an infant with a retinitis due to a postnatally acquired Cytomegalovirus, successfully treated at six months of life with three cycles of intravitreal injections of pegaptanib sodium. The therapy was effective in modulating the retinal disease activity in this immunocompetent child, without any side effect observed at a long-term follow up.

Keywords:
cytomegalovirus infection neonatal retinitis newborn infant Pegaptanib sodium

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

Figures

References:

[1]	Piersigilli F, Catena G, De Gasperis MR et al. Active retinitis in an infant with postnatally acquired cytomegalovirus infection. J Perinatol. 32:559-62. 2012.
[2]	Coors LE, Spencer R Delayed presentation of cytomegalovirus retinitis in an infant with severe congenital cytomegalovirus infection. Retina, (4 Suppl):S59-62. Apr; 2010
[3]	Costagliola C, Romano MR, Parmeggiani F et al. Epiretinal membrane in a 12-year-old immunocompetent girl with cytomegalovirus infection. Eur J Ophthalmo, 19:1098-101. 2009.
[4]	Crooke ST. Vitravene-another piece in the mosaic. Antisense Nucleic Acid Drug Dev, 8:vii-viii1998
[5]	Ng EW, Shima DT, Calias P et al. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discover, 5:123-132. 2006.
[6]	Gragoudas ES, Adamis AP, Cunningham ET Jr, et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med, 351:2805-2816. 2004.
[7]	The Eyetech Study Group. Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylatedaptamer (EYE001) for the treatment of exudative age-related macular degeneration. Retina, 22:143-152. 2002.